Effects of varenicline as an adjunct to analgesic and anti-inflammatory therapy in acute nerve injury.

INTRODUCTION Acute nerve injury (ANI) leads to significant neuropathic pain and functional impairment. Current treatments, including nonsteroidal anti-inflammatory drugs (NSAIDs) like meloxicam, provide symptomatic relief but have limited neuroregenerative effects. Varenicline, a nicotinic acetylcholine receptor (nAChR) agonist, has demonstrated neuroprotective and anti-inflammatory properties. AIM This study evaluates the effects of varenicline as an add-on therapy to meloxicam in a rat model of ANI. METHODS Eighteen female Wistar rats were randomized into four groups: Control (CONT), Sham (SHAM), Acute Nerve Injury + Meloxicam (ANI+Melox), and Acute Nerve Injury + Meloxicam + Varenicline (ANI+Melox+VAR). Varenicline (2.5 mg/kg, s.c.) was administered alongside meloxicam (2 mg/kg, s.c.). Functional recovery, histopathological changes, and biochemical markers, including prostaglandins (PGE₂, PGI₂), substance P, IL-6, levels, were assessed after 30 days. RESULTS Varenicline and meloxicam co-treatment significantly reduced inflammatory and pain biomarkers including prostaglandins, interleukin-6 and substance P, compared to meloxicam alone. Histopathological evaluation revealed enhanced Schwann cell proliferation, reduced fibrosis, and increased Bands of Büngner formation, suggesting nerve regeneration. CONCLUSION Varenicline, as an adjunct to meloxicam, enhances neuroprotection, reduces inflammation, and promotes histological and biochemical indicators of regeneration in rats with acute sciatic nerve injury. Future studies should explore its long-term effects and potential as a monotherapy for peripheral nerve injuries.

• Publication year

  2025

• Venue

  Injury

• Publication date

  2025-11-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.injury.2025.112908PMID 41317660
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nicotinic acetylcholine receptor-mediated effects of varenicline on LPS-elevated prostaglandin and cyclooxygenase levels in RAW 264.7 macrophages

  2024cited by this paper
• Exploring Cholinergic Compounds for Peripheral Neuropathic Pain Management: A Comprehensive Scoping Review of Rodent Model Studies

  2023cited by this paper
• Nicotine Decreases Nerve Regeneration and Pain Behaviors via PTEN and Downstream Inflammation-Related Pathway in Two Rat Nerve Injury Models

  2023cited by this paper
• Short-Term Collagen Nerve Wrapping Facilitates Motor and Sensory Recovery from Nerve Degeneration in a Sciatic Nerve Injury Rat Model

  2023cited by this paper
• The effect of taxifolin on oxidative sciatic nerve damage induced by cobalt chloride in rats: a biochemical and histopathological evaluation.

  2022cited by this paper
• Evaluation methods of a rat sciatic nerve crush injury model.

  2022cited by this paper
• Targeting α7 nicotinic acetylcholine receptors for chronic pain

  2022cited by this paper
• Varenicline Prevents LPS-Induced Inflammatory Response via Nicotinic Acetylcholine Receptors in RAW 264.7 Macrophages

  2021cited by this paper
• Complications after sciatic nerve defect repair in rats

  2020cited by this paper
• Atlas of Normal Microanatomy, Procedural and Processing Artifacts, Common Background Findings, and Neurotoxic Lesions in the Peripheral Nervous System of Laboratory Animals

  2020cited by this paper
• Comparison of the Effects of Extracorporeal Irradiation and Liquid Nitrogen on Nerve Recovery in a Rat Model

  2020cited by this paper
• Effects of cessation of cigarette smoking on eicosanoid biomarkers of inflammation and oxidative damage

  2019cited by this paper
• Varenicline increases random flap survival in rats submitted to nicotine

  2018cited by this paper
• A morphological and biochemical evaluation of the effects of quercetin on experimental sciatic nerve damage in rats

  2018cited by this paper
• Inhibition of peripheral macrophages by nicotinic acetylcholine receptor agonists suppresses spinal microglial activation and neuropathic pain in mice with peripheral nerve injury

  2018cited by this paper
• Varenicline is a smoking cessation drug that blocks alveolar expansion in mice intratracheally administrated porcine pancreatic elastase.

  2018cited by this paper
• Sciatic nerve injury following analgesic drug injection in rats: A histopathological examination

  2018cited by this paper
• Effects of varenicline and nicotine replacement therapy on arterial elasticity, endothelial glycocalyx and oxidative stress during a 3-month smoking cessation program.

  2017cited by this paper
• Delayed Varenicline Administration Reduces Inflammation and Improves Forelimb Use Following Experimental Stroke.

  2017cited by this paper
• Axonal regeneration in early stages of sciatic nerve crush injury is enhanced by α7nAChR in rats

  2015cited by this paper
• Peripheral alpha4beta2 nicotinic acetylcholine receptor signalling attenuates tactile allodynia and thermal hyperalgesia after nerve injury in mice

  2015cited by this paper
• Antinociceptive effect of clavulanic acid and its preventive activity against development of morphine tolerance and dependence in animal models

  2014cited by this paper
• Investigation of the dose-dependency of citicoline effects on nerve regeneration and functional recovery in a rat model of sciatic nerve injury.

  2014cited by this paper
• Neuroinflammation and the generation of neuropathic pain.

  2013cited by this paper
• Preventive effect of varenicline on impairment of endothelial function in cerebral vessels induced by acute smoking in rats

  2012cited by this paper
• Meloxicam Exerts Neuroprotection on Spinal Cord Trauma in Rats

  2011cited by this paper
• Citicoline improves functional recovery, promotes nerve regeneration, and reduces postoperative scarring after peripheral nerve surgery in rats.

  2007cited by this paper
• Varenicline Is a Partial Agonist at α4β2 and a Full Agonist at α7 Neuronal Nicotinic Receptors

  2006cited by this paper
• Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors.

  2006cited by this paper
• Systemic Meloxicam Reduces Tactile Allodynia Development After L5 Single Spinal Nerve Injury in Rats

  2005cited by this paper
• Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation

  2005cited by this paper
• Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.

  2005cited by this paper

• No citing papers are available for this paper.